Segmentation by type distinguishes four operational categories that shape the supply‑side economics of the market. Expression‑host services encompass vector design, host‑cell engineering, and scale‑up across bacterial (E. coli), yeast, insect, and mammalian platforms; the choice of host determines yield, post‑translational fidelity, and cost, making this segment the largest cost driver. Purification and downstream processing includes affinity chromatography, ion‑exchange, and size‑exclusion workflows, each priced according to resin consumption and process complexity; high‑purity therapeutic candidates push premium pricing. Analytical and functional validation offers activity assays, binding kinetics, and stability profiling, which add value by reducing client‑side development cycles. Custom labeling and conjugation services such as fluorescent tagging, biotinylation, or PEGylation address niche assay or formulation needs and command higher margins due to specialized chemistry. The revenue contribution of each type mirrors the client development stage: early‑stage projects rely heavily on expression and purification, whereas late‑stage therapeutic programs allocate a larger share to validation and labeling, collectively defining the market taxonomy for recombinant protein services.